Hepatitis C wata cuta ce ta hanta da Hepatitis C virus (HCV) ke haddasawa. Ana kiran ta Hepatitis C saboda tana haifar da kumburi da lalacewar ƙwayoyin hanta. Ba kamar wasu nau’o’in hepatitis da ake iya yaɗa su ta abinci ko ruwa ba, HCV ta fi yaɗuwa ne ta hanyar jini mai ɗauke da ƙwayar cutar. Saboda haka, tarihin ƙarin haɗarin kamuwa da cutar yana da alaƙa sosai da amfani da allura ko kayan aiki masu ɗauke da jini, ƙarin jinin da ba a yi masa cikakken gwaji ba, da wasu hanyoyin da jini daga mai ɗauke da cutar zai iya shiga jikin wani.
Muhimmin abin da ya bambanta Hepatitis C da wasu cututtuka shi ne yawan kasancewarta ba tare da alamomi ba. Mutum na iya kamuwa da HCV na tsawon shekaru masu yawa ba tare da ya san yana ɗauke da ita ba. A lokacin da alamomi suka bayyana, cutar na iya kasancewa ta riga ta haifar da babban lahani ga hanta. Wannan yanayin na rashin bayyana yana daga cikin manyan dalilan da suka sa ake buƙatar gwajin jini domin gano cutar maimakon jiran bayyanar alamomi.
Hepatitis C na iya kasancewa mai saurin warkewa ko kuma ta zama mai dawwama. Bayan kamuwa da HCV, wani ɓangare na mutane kan kawar da kwayar cutar da ƙarfin garkuwar jikinsu ba tare da magani ba, amma mafi yawan waɗanda ba su kawar da ita ba suna iya shiga matakin chronic infection. WHO ta kiyasta cewa kusan kashi 30% na masu kamuwa da HCV na iya kawar da ƙwayar cutar cikin watanni shida ba tare da magani ba, yayin da sauran ke iya ci gaba har zuwa chronic hepatitis C.
Idan chronic hepatitis C ta ci gaba ba tare da an gano ta ba, kumburin hanta na dogon lokaci na iya haifar da fibrosis, wato taruwar taɓon nama a hanta. Idan wannan lalacewar ta yi tsanani, tana iya kaiwa ga cirrhosis, sannan cirrhosis na iya ƙara haɗarin hepatocellular carcinoma, wato babban nau’in kansar hanta. Amma ba lallai ne kowane mai HCV ya kai ga waɗannan matakai ba; saurin cigaban cutar yana bambanta daga mutum zuwa mutum.
Babban sauyi da aka samu a tarihin Hepatitis C shi ne cewa cutar wadda a da take da wahalar magani yanzu tana daga cikin cututtukan ƙwayoyin cuta da za a iya warkar da su da maganin baki na tsawon makonni kaɗan. Magungunan zamani da ake kira direct-acting antivirals (DAAs) suna iya warkar da fiye da kashi 95% na masu HCV a yawancin yanayi. Wannan ya sauya Hepatitis C daga cutar da ake yawan sarrafawa ba tare da cikakkiyar kawar da ƙwayar cutar ba zuwa cutar da ake iya warkar da ita.
Duk da wannan cigaban kimiyya, matsalar Hepatitis C ba ta ƙare ba. Babban ƙalubalen yanzu shi ne gano mutanen da ba su san suna ɗauke da cutar ba da kuma tabbatar da cewa waɗanda aka gano sun samu magani. WHO ta nuna cewa a faɗin duniya har zuwa yanzu akwai babban giɓi tsakanin adadin masu kamuwa da cutar da waɗanda aka gano aka kuma yi wa magani.
Ma’anar Hepatitis C
Hepatitis C ita ce cutar da ke kama hanta da ƙwayar cutar Hepatitis C ke haddasawa, inda ƙwayar cutar ke shiga jikin mutum, ta isa ga sassan hanta, ta yi amfani da tsarin ƙwayoyin jiki wajen samar da sababbin ƙwayoyin cutar, sannan ta jawo rikicewar garkuwar jiki da kumburin hanta.
HCV wata ƙwayar cuta ce mai ɗauke da RNA, kuma tana cikin rukunin Flaviviridae, a cikin jinsin Hepacivirus. Wannan bayanin yana da muhimmanci saboda tsarin ƙwayar cutar da bambancin ƙwayoyin halittarta ne suka taimaka wajen fahimtar dalilin da ya sa magungunan zamani suke kai hari ga wasu enzymes da proteins na HCV. Binciken kwayar cutar ya nuna cewa RNA ɗinta tana da kusan nucleotides 10,000 kuma tana da tsarin positive-strand RNA.
Hepatitis C ba cuta ce da ake tantance ta kawai da cewa hanta ta kumbura ba. Ana bambance HCV infection da sauran abubuwan da ke iya haifar da hepatitis ta hanyar gano alamomin da ke nuna cewa jikin mutum ya taɓa haɗuwa da HCV, sannan a tabbatar ko kwayar cutar tana nan a jini a halin yanzu.
Wannan bambanci yana da matuƙar muhimmanci. Anti-HCV antibody yana nuna cewa mutum ya taɓa fuskantar HCV, amma ba ya tabbatar da cewa har yanzu kwayar cutar tana cikin jikinsa. Mutumin da ya kawar da HCV da kansa ko wanda aka warkar da shi ta hanyar magani na iya ci gaba da kasancewa anti-HCV positive. Saboda haka, HCV RNA ne ake amfani da shi wajen tabbatar da cewa akwai active infection.
A bangaren cutar, ana iya raba Hepatitis C zuwa manyan matakai biyu. Acute hepatitis C ita ce matakin farko bayan sabuwar kamuwa da HCV, wanda WHO ke bayyana shi a matsayin farkon watanni shida bayan kamuwa. Idan garkuwar jiki ba ta kawar da kwayar cutar ba, infection ɗin na iya zama chronic hepatitis C, wato cutar da ke ci gaba da kasancewa cikin jiki na dogon lokaci.
Muhimmin abin lura shi ne cewa hepatitis C mai tsanani ba daidai take da cirrhosis ba. Tsanantar cutar na iya kasancewa ba tare da babban tabon hanta ba a farkon shekaru. Amma kumburin da ya daɗe yana iya jawo fibrosis a hankali. Idan fibrosis ta kai wani mataki mai tsanani, sai a samu cirrhosis. Wannan matsalar ba ta faruwa da sauri ko daidai ga kowa.
Saboda haka, ma’anar Hepatitis C a fannin ilimin likitanci ta haɗa abubuwa uku: HCV infection, martanin jikin mutum ga kwayar cutar, da kuma yiwuwar samun cigaba daga kamuwa da cuta zuwa lalacewar hanta mai tsanani. Fahimtar waɗannan matakai yana taimakawa wajen gane dalilin da ya sa gano cutar da wuri da kuma magance ta kafin fibrosis ta yi tsanani yake da muhimmanci.
Tarihin gano Hepatitis C
Tarihin Hepatitis C ya bambanta da na Hepatitis A da B bisa dalili na dogon lokaci masana kimiyya ba su san kwayar cutar da ke haddasa wani babban nau’in hepatitis da ake kira non-A, non-B hepatitis ba. An lura cewa wasu mutane suna kamuwa da hepatitis bayan ƙarin jini ko wasu hanyoyin ta’ammali da jini, amma gwaje-gwajen Hepatitis A da B ba sa gano wannan cuta. Wannan ya haifar da tambayar: wace kwayar cuta ce ke haddasa wannan non-A, non-B hepatitis?
A shekara ta 1989, wata tawaga da Qui-Lim Choo, George Kuo, Amy Weiner, Lacy Overby, Daniel Bradley da Michael Houghton suka jagoranta ta sami wani muhimmin cigaba. Sun ware wani cDNA clone daga wata kwayar cutar da ke da alaƙa da non-A, non-B hepatitis. Binciken ya nuna cewa abin da aka gano ya samo asali ne daga RNA na wani sabuwar ƙwayar cuta, ba daga DNA na mai cutar ba. Wannan binciken ne ya ba da hujjar farko mai ƙarfi ta gano HCV.
A wannan shekarar kuma, George Kuo da abokan aikinsa suka samar da wani gwajin da zai iya gano antibodies da jikin mutum yake samarwa a kan HCV. Wannan ya kasance babban sauyi saboda kafin samuwar irin wannan gwaji, gano non-A, non-B hepatitis ya dogara sosai da alamomin asibiti da kawar da wasu dalilai.
Binciken Harvey Alter da abokan aikinsa ya ƙara tabbatar da muhimmancin HCV wajen hepatitis da ke biyo bayan ƙarin jini. Sun gano antibodies ga HCV a cikin mutanen da suka samu acute da chronic non-A, non-B hepatitis, kuma binciken ya nuna cewa gwajin masu bayar da jini na iya taimakawa wajen hana yaduwar irin wannan hepatitis.
Gano HCV ya buɗe ƙofa ga wani sabon zamani na bincike. Masana sun fara fahimtar tsarin kwayar cutar, yadda take shiga da amfani da ƙwayoyin hanta, da kuma enzymes da take buƙata domin ta samar da kanta. Daga baya aka gano muhimman sassa kamar NS3/4A protease, NS5A da NS5B polymerase, waɗanda suka zama muhimman wuraren da magungunan zamani ke kai hari.
A shekara ta 2020, an ba Harvey J. Alter, Michael Houghton da Charles M. Rice lambar yabo ta Nobel Prize in Physiology or Medicine saboda rawar da suka taka wajen gano HCV.
Gudummawar Charles Rice ta kasance musamman wajen tabbatar da cewa HCV da aka gano shi kaɗai ne ke iya haddasa cutar. Wannan ya taimaka wajen tabbatar da alaƙar da ke tsakanin kwayar cutar da hepatitis, tare da samar da tushen binciken da ya kai ga fahimtar rayuwar HCV da samar da magunguna masu kai hari kai tsaye ga kwayar cutar.
Nau’ikan Hepatitis C
Hepatitis C marar tsanani
Acute Hepatitis C ita ce farkon matakin infection bayan mutum ya kamu da HCV. Ana amfani da kalmar acute ne musamman wajen bayyana farkon watanni shida bayan kamuwa. Abin da ya bambanta wannan mataki shi ne cewa wasu mutane suna iya kawar da kwayar cutar da ƙarfin garkuwar jikinsu ba tare da magani ba.
Amma ba za a iya dogaro da bayyanar alamomi wajen gane wanda zai kawar da cutar da wanda zai ci gaba da chronic infection ba. Saboda haka, gano HCV RNA bayan kamuwa yana da muhimmanci wajen bin diddigin infection.
Hepatitis C mai tsanani
Idan HCV ya ci gaba da kasancewa a jikin mutum bayan matakin acute, ana ɗaukar infection ɗin a matsayin chronic. Wannan shi ne matakin da ya fi zama abin damuwa saboda kwayar cutar na iya kasancewa cikin jiki na shekaru da dama ba tare da bayyanar manyan alamomi ba.
A hankali, kumburin da ke faruwa a hanta na iya haifar da fibrosis. Wasu mutane na iya samun ƙaramin ci gaba na fibrosis na tsawon shekaru, yayin da wasu ke samun saurin lalacewar hanta saboda wasu abubuwan ƙara haɗari.
Hepatitis C mai genotype daban-daban
HCV ba kwayar cuta ce mai nau’in kwayoyin halitta guda ɗaya ba. Tana da genotypes da kuma ƙananan nau’o’in kwayoyin halitta. Wannan bambancin ya kasance mai muhimmanci musamman a zamanin magungunan interferon, lokacin da genotype ke da tasiri sosai ga yiwuwar samun nasarar magani.
A zamanin magungunan DAA na yanzu, muhimmancin genotype ya ragu saboda akwai magungunan pan-genotypic da ke aiki a kan genotypes da dama. Wannan ci gaba ya sauƙaƙa tsarin magani kuma ya rage buƙatar rarrabe magani bisa genotype a wasu marasa lafiya. WHO yanzu tana ba da shawarar pan-genotypic DAA ga mutanen da ke da chronic HCV.
Hanyoyin yaɗuwa
Babbar hanyar yaɗuwar HCV ita ce shigar jinin mai ɗauke da kwayar cutar cikin jinin ko tantanin wani mutum. Wannan shi ne dalilin da ya sa HCV ake kira blood-borne virus.
Ƙarin jini
A tarihi, ƙarin jini da kayan jini da ba a yi musu gwajin HCV ba sun kasance muhimmiyar hanyar yaɗuwa. Samuwar gwajin anti-HCV da fara amfani da shi wajen tantance masu bayar da jini ya rage wannan hanyar yaɗuwa sosai a ƙasashen da ke da ingantaccen tsarin gwajin jini.
A wuraren da ake sake amfani da allura ko kayan aikin lafiya ba tare da cikakken tsaftacewa da sterilization ba, mutum na iya samun HCV daga ƙananan adadin jini da ya rage a kayan aikin. Wannan na sa infection prevention and control ya zama muhimmin ginshiƙi wajen hana cutar.
Raba allurai da syringes tsakanin mutanen da ke amfani da magungunan da ake yi wa allura yana daga cikin manyan hanyoyin yaɗuwar HCV a duniya. WHO ta kiyasta cewa mutanen da suke yin amfani da magungunan da ake yi wa allura suna da muhimmiyar rawa wajen sabbin infections na duniya.
Abubuwa masu kaifi
HCV kuma na iya yaɗuwa ta wasu hanyoyin da ke haifar da hulɗa da jini, kamar kayan yin tattoo ko abubuwa masu kaifi da tsini da ba a sarrafa su yadda ya kamata, ko wasu hanyoyin gargajiya da ke amfani da kayan yanka ko huda fata idan kayan sun gurɓata da jini.
Sauran hanyoyi
Daga uwa zuwa jariri ma yana yiwuwa, amma wannan ba ita ce babbar hanyar yaɗuwar HCV ba. Haka kuma, yaɗuwar ta hanyar jima’i tana yiwuwa, musamman idan akwai hulɗa da jini ko wasu yanayi masu ƙara haɗari, amma gabaɗaya ta fi ƙarancin tasiri fiye da yaɗuwar kai tsaye ta jini.
HCV ba ya yaɗuwa ta hanyar cin abinci ko shan ruwa tare, runguma, musafaha, ko zama kusa da mai cutar. WHO ta bayyana cewa ba a yaɗa HCV ta hanyar nono, abinci, ruwa ko hulɗar yau da kullum kamar sumbata da raba abinci ko abin sha.
Alamomin Hepatitis C
Babban ƙalubalen gano Hepatitis C shi ne cewa mafi yawan masu kamuwa ba sa nuna alamomi a farkon cutar. Wannan yana iya sa mutum ya kasance yana ɗauke da HCV na dogon lokaci ba tare da saninsa ba.
Idan alamomin acute infection suka bayyana, suna iya haɗawa da gajiya, rashin cin abinci, tashin zuciya, amai, ciwon ciki, zazzabi, ciwon gabobi, fitsari mai duhu da kuma jaundice, wato rawayar fata ko fararen idanu. Amma jaundice ba ta faruwa ga kowane mai HCV ba.
A chronic infection, alamomin na iya zama marasa takamaiman yanayi. Mutum na iya jin gajiya, rashin kuzari ko rashin jin daɗin jiki ba tare da wani abu da zai nuna kai tsaye cewa matsalar tana hanta ba. Wannan ne ya sa wasu marasa lafiya suke zuwa asibiti ne bayan gwajin jini na wani dalili daban ya nuna matsalar enzymes na hanta.
Idan cutar ta kai ga advanced liver disease, alamomi na iya sauyawa saboda ba HCV kanta kawai ake gani ba, sai sakamakon lalacewar aikin hanta. Ana iya samun kumburin ciki saboda ascites, kumburin ƙafafu, zubar jini cikin sauƙi, rikicewar tunani saboda hepatic encephalopathy, rawayar fata da sauran alamomin decompensated cirrhosis.
Illoli da matsalolin cutar
Babbar matsalar chronic HCV ita ce ci gaba da lalacewar hanta a hankali. Ƙwayar cutar da martanin garkuwar jiki na iya haifar da kumburi wanda a tsawon lokaci yake ƙara tabon nama a hanta.
Fibrosis
Fibrosis ita ce taruwar tabon nama a hanta sakamakon ci gaba da lalacewar ƙwayoyin hanta. Ana iya ɗaukar fibrosis a matsayin matakin da ke tsakanin kumburin hanta mai ɗorewa da cirrhosis. Ba kowane mai HCV ne fibrosis ɗinsa zai ci gaba da sauri ba, kuma akwai bambancin ci gaba tsakanin mutane.
Cirrhosis
Idan fibrosis ta yi tsanani, tsarin hanta yana sauyawa har ta rasa wani ɓangare na aikinta na yau da kullum. Wannan shi ne cirrhosis. WHO ta kiyasta cewa a cikin chronic HCV, haɗarin cirrhosis a cikin shekaru 20 yana tsakanin kusan 15% zuwa 30%, ko da yake haɗarin ya bambanta da mutum da abubuwan da ke tare da shi.
Kansar hanta
Mutanen da suka samu cirrhosis sakamakon HCV suna da ƙarin haɗarin hepatocellular carcinoma (HCC). CDC ta nuna cewa mutanen da ke da hepatitis C da cirrhosis suna da kusan 1%–4% na kamuwa da HCC.
Wasu ƙarin matsalolin
HCV ba ya shafar hanta kaɗai. Wasu masu chronic HCV na iya samun mixed cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda, wasu cututtukan lymphatic kamar non-Hodgkin lymphoma, da wasu matsalolin metabolism.
Hanyoyin gwaje-gwaje
Binciken Hepatitis C yana da matakai biyu masu muhimmanci.
Gwajin anti-HCV
Mataki na farko shi ne gwajin jini na anti-HCV antibody. Wannan gwajin yana bincika ko garkuwar jikin mutum ta taɓa yin martani ga HCV.
Idan sakamakon ya kasance negative, yawanci yana nufin ba a gano hujjar cewa mutum ya taɓa kamuwa da HCV ba. Amma idan kamuwa da cutar ya faru kwanan nan, antibody na iya kasancewa bai bayyana ba tukuna. Saboda haka, tarihin fallasa jini da lokacin da aka samu fallasar suna da muhimmanci wajen fassara sakamakon.
Gwajin HCV RNA
Idan anti-HCV ya kasance positive/reactive, ana buƙatar gwajin HCV RNA, wato nucleic acid test (NAT), domin gano ko akwai kwayar cutar a jini a halin yanzu. Wannan mataki yana bambance mutum wanda ya taɓa kamuwa amma ya kawar da cutar daga wanda har yanzu yana da active infection. Wannan yana da muhimmanci saboda anti-HCV positive ba yana nufin active hepatitis C kai tsaye ba.
Tantance lalacewar hanta
Bayan tabbatar da active HCV infection, ana tantance matsayin hanta. Ana iya amfani da gwaje-gwajen jini da dabarun lissafi kamar FIB-4, sannan a yi amfani da ultrasound ko transient elastography (FibroScan) wajen kimanta fibrosis da cirrhosis. A wasu yanayi na musamman, ana iya yin liver biopsy, amma ba lallai ne ta zama dole ga kowane mara lafiya ba.
Wasu ƙarin gwaje-gwajen
Ana iya bincika ALT da AST, platelet count da sauran alamomin aikin hanta. Haka kuma, kafin magani ana iya bincika HIV da Hepatitis B saboda co-infection na iya shafar kulawa da marar lafiya. CDC ta kuma ba da shawarar a duba bukatar rigakafin Hepatitis A da B ga masu HCV.
Magunguna da kariya
Babbar nasarar maganin Hepatitis C shi ne zuwan direct-acting antivirals (DAAs). Waɗannan magunguna suna kai hari kai tsaye ga muhimman proteins ko enzymes da HCV ke buƙata domin ta yawaita.
A baya, ana amfani da interferon tare da ribavirin, wanda maganinsa ya daɗe, yana da illoli masu yawa kuma ba ya samun nasara kamar magungunan zamani. A yau, irin wannan tsarin ba shi ne babban zaɓin farko ba; DAA sun fi sauƙin sha, sun fi inganci kuma suna da ƙarancin illoli.
Yawancin tsarin DAA na zamani ana sha ne ta baki na kusan makonni 8–12, kuma suna iya warkar da fiye da 95% na masu HCV. WHO tana ba da shawarar magungunan pan-genotypic DAA ga manya, matasa da yara daga shekara uku zuwa sama da ke da chronic HCV.
Manufar magani ita ce a kawar da HCV RNA daga jini har ya kai matakin da ba a sake gano shi ba bayan an kammala magani. Wannan shi ake kira sustained virologic response (SVR), kuma a aikace ana ɗaukar SVR a matsayin warkewa daga HCV.
Duk da warkewa, mutum na iya sake kamuwa da HCV idan ya sake fuskantar jinin da ke ɗauke da kwayar cutar. Saboda haka, warkewa ba ya samar da immunity mai ɗorewa kamar yadda wasu vaccines ke yi.
Ga mutumin da ya riga ya samu cirrhosis, warkar da HCV na rage haɗarin ci gaba da lalacewar hanta, amma ba ya nufin cewa duk haɗarin kansar hanta ya ɓace. Mutanen da suka kai ga cirrhosis na iya ci gaba da buƙatar kulawar hepatology da surveillance na kansar hanta ko da bayan an kawar da HCV.
Hanyoyin rigakafi
A halin yanzu babu ingantacciyar allurar rigakafin Hepatitis C. Wannan ya bambanta Hepatitis C da Hepatitis B, wadda ke da vaccine mai inganci. Saboda haka, rigakafin HCV ya fi dogara ne kan hana jini mai ɗauke da kwayar cutar shiga jikin mutum.
A asibitoci da cibiyoyin lafiya, ya kamata a tabbatar da cewa allurai da kayan aikin lafiya ba a sake amfani da su ba sai idan an tsara su musamman domin sterilization mai inganci. Haka kuma, ya kamata a yi gwajin jinin masu bayar da jini kafin amfani da shi.
A wuraren tattoo, piercing da wasu ayyukan da ke iya huda fata, amfani da kayan aiki marasa gurɓata yana da muhimmanci. Kada a raba abubuwan da za su iya samun jini kamar reza, allurar sirinji ko wasu kayan yanka fata.
Ga mutanen da suke amfani da magungunan da ake yi wa allura, shirye-shiryen harm reduction, musamman samun allura da syringes masu tsabta da kuma kula da dogaro da ƙwayoyi, na daga cikin dabarun rage yaɗuwar HCV.
Rigakafin yaɗuwar cutar ta hanyar jima’i ya fi zama muhimmiyar magana ga mutanen da ke cikin yanayin da hulɗar jima’i ke iya haɗawa da jini. Haka kuma, mutumin da aka tabbatar yana da HCV ya kamata ya samu shawarar ƙwararren ma’aikacin lafiya kan yadda zai rage yiwuwar yaɗawa.
HEpatitis C a Najeriya
Hepatitis C na daga cikin matsalolin viral hepatitis da ke buƙatar kulawa a Najeriya, amma bayanan ƙasa baki ɗaya ba su da sauƙin kwatantawa saboda binciken da ake da shi ya bambanta wajen yawan mutane da aka bincika, yankin da aka gudanar da binciken, shekarun mahalarta da irin gwajin da aka yi.
Rahoton Nigeria Demographic and Health Survey 2024 ya nuna cewa ana amfani da kimar kusan 1.1% a matsayin national prevalence na HCV, tare da HBV a kusan 8.1%. Rahoton ya kuma nuna cewa viral hepatitis na ci gaba da kasancewa matsalar lafiyar jama’a a Najeriya, kuma ƙasar tana da manufar kawar da viral hepatitis a matsayin babbar matsalar lafiyar jama’a zuwa 2030.
Sai dai ya kamata a kula sosai wajen fassara irin waɗannan lambobi. Wani babban systematic review da meta-analysis na shekarar 2024 wanda ya tattara bincike 130 daga ƙasashen sub-Saharan Africa ya nuna cewa Najeriya ce ƙasar da ta ba da yawan datasets a cikin binciken, amma an samu babban bambancin sakamakon bincike tsakanin wurare da lokuta. Wannan yana nuna cewa ba daidai ba ne a ɗauki sakamakon wani ƙaramin binciken asibiti a matsayin cikakken national prevalence.
A Najeriya, hanyoyin da ke buƙatar kulawa ta musamman sun haɗa da lafiyar jini da transfusion, infection prevention a cibiyoyin lafiya, kayan aikin da ke huda fata, da gwaji da magani ga mutanen da ke cikin ƙarin haɗari. Wannan yana da muhimmanci saboda HCV ba ta da vaccine, amma tana da maganin warkarwa mai matuƙar inganci.
Binciken da aka yi a sub-Saharan Africa ya nuna cewa yawan HCV antibody positivity yana bambanta sosai tsakanin yankuna da ƙungiyoyin mutane. Meta-analysis ɗin ya kiyasta weighted seroprevalence na yankin Africa-Western da kusan 2.88%, amma wannan ba daidai yake da national prevalence na Najeriya ba. Wannan bambanci yana nuna muhimmancin amfani da bayanan Najeriya na ƙasa yayin tsara manufofi.
Wasu ƙungiyoyin jama’a a Najeriya na iya kasancewa cikin ƙarin haɗari. Misali, wani systematic review na correctional facilities a Najeriya ya gano babban bambanci tsakanin binciken da aka gudanar a gidajen yari, inda sakamakon HCV ya bambanta sosai tsakanin wurare. Masu binciken sun kiyasta pooled prevalence na HCV a cikin fursunonin Najeriya kusan 10%, amma sun jaddada babban heterogeneity tsakanin binciken. Wannan ba za a mayar da shi matsayin prevalence na jama’ar Najeriya gaba ɗaya ba; yana nuna ne cewa wasu ƙungiyoyin da ke cikin yanayi na musamman na iya samun haɗari mafi girma.
Babban ƙalubalen Najeriya shi ne cewa samun magani mai warkarwa bai isa ba idan ba a gano masu cutar ba. Saboda HCV na iya kasancewa ba tare da alamomi ba, tsarin kawar da cutar yana buƙatar haɗa gwaji, tabbatar da HCV RNA, tantance lalacewar hanta, samun DAA, da kuma bin mara lafiya har bayan magani.
A matakin lafiyar jama’a, Najeriya na iya samun babban amfani daga tsarin da WHO ke ƙarfafawa na decentralization da task-shifting, inda horarrun ma’aikatan lafiya a matakin primary healthcare za su iya taimakawa wajen gwaji, tantancewa da ba da magani ga marasa lafiya masu dacewa. Wannan ya fi dacewa da cutar da maganinta ya zama mai sauƙi fiye da yadda yake a zamanin interferon.
Manazarta
Centers for Disease Control and Prevention. (2025, January 31). Clinical care of hepatitis C. CDC.
Leone, N., & Rizzetto, M. (2005). Natural history of hepatitis C virus infection: From chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterologicae Dietologica, 51(1), 31–46.
National Population Commission (NPC) [Nigeria] & ICF. (2025). Nigeria Demographic and Health Survey 2024. National Population Commission and ICF.
World Health Organization. (2026, April 28). Global hepatitis report 2026. WHO.
Sharuɗɗan Editoci
Duk maƙalun da ku ka karanta a wannan taska ta Bakandamiya, marubuta, manazarta da editocinmu ne suka rubuta tare da sa idon kwamitin ba da shawara na ƙwararru. Kuma kowace maƙala da aka buga ta bi muhimman matakai na tantancewa don ganin cewa bayanan dake cikinta sun inganta.
Idan kuma an ga wani kuskure a cikin kowace maƙalarmu, a sanar da mu. Za mu yi bincike sannan mu gyara gwargwadon fahimtarmu.